KDR and hepatocellular carcinoma: Indeed, VEGFs and their receptor VEGFR2 are activated in HCC; therefore, the major molecular targets are inhibited by various receptor tyrosine kinase inhibitors, such as sorafenib [10], regorafenib, lenvatinib [11], and cabozantinib [12], and monoclonal antibodies, such as bevacizumab [13] and ramucirumab [14], for the treatment of patients with advanced-stage HCC [15].